غير مصنف

Thompson Investment Management Decreased Its Northern Trust (NTRS) Stake; Shorts at Actinium Pharmaceuticals (delaware (NYSEAMERICAN:ATNM) Lowered By 9.3%

 


Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Logo

Thompson Investment Management Inc decreased Northern Trust Corp (NTRS) stake by 4.59% reported in 2018Q3 SEC filing. Thompson Investment Management Inc sold 3,176 shares as Northern Trust Corp (NTRS)’s stock declined 17.12%. The Thompson Investment Management Inc holds 65,977 shares with $6.74 million value, down from 69,153 last quarter. Northern Trust Corp now has $19.63B valuation. The stock decreased 0.21% or $0.19 during the last trading session, reaching $89.64. About 1.21 million shares traded. Northern Trust Corporation (NASDAQ:NTRS) has declined 9.37% since February 10, 2018 and is downtrending. It has underperformed by 9.37% the S&P500. Some Historical NTRS News: 17/04/2018 – NORTHERN TRUST CORP – QTRLY RETURN ON AVERAGE COMMON EQUITY WAS 16.0 PCT VS 11.6 PCT REPORTED LAST YEAR; 21/04/2018 – DJ Northern Trust Corporation, Inst Holders, 1Q 2018 (NTRS); 09/04/2018 – Northern Trust Appoints Managing Director for Bonita Springs Office; 17/04/2018 – NORTHERN TRUST AUM $1.17T; 17/04/2018 – Northern Trust 1Q Rev $1.5B; 24/04/2018 – GLOBAL BANKS: UBS SAYS IT IS OVERWEIGHT ON US BANKS; 17/04/2018 – Northern Trust 1Q Net $381.6M; 17/04/2018 – NORTHERN TRUST 1Q EPS $1.58; 14/05/2018 – Northern Trust Roadshow Set By Loop Capital Markets for May. 21; 17/04/2018 – NORTHERN TRUST 1Q EPS $1.58, EST. $1.41

Actinium Pharmaceuticals Inc (delaware (NYSEAMERICAN:ATNM) had a decrease of 9.3% in short interest. ATNM’s SI was 2.97 million shares in February as released by FINRA. Its down 9.3% from 3.28M shares previously. With 1.08M avg volume, 3 days are for Actinium Pharmaceuticals Inc (delaware (NYSEAMERICAN:ATNM)’s short sellers to cover ATNM’s short positions. The stock decreased 4.30% or $0.0234 during the last trading session, reaching $0.5212. About 272,812 shares traded. Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) has declined 38.07% since February 10, 2018 and is downtrending. It has underperformed by 38.07% the S&P500. Some Historical ATNM News: 14/03/2018 – Actinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory Affairs; 13/03/2018 Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or; 14/03/2018 – Actinium Pharmaceuticals Announces Appointment of Jehan Rowlands as Vice-Pres, Head of Regulatory Affairs; 14/05/2018 – Actinium at Non-Deal Roadshow Hosted By Goetzpartners Today; 28/03/2018 – Actinium Pharmaceuticals Announces Collaborative Research Partnership With Astellas Leveraging Actinium’s AWE Platform Technology; 01/05/2018 – Actinium Pharmaceuticals Appoints Dr. Jeffrey Chell to Its Board of Directors; 09/04/2018 – Actinium Pharmaceuticals Inc (ATNM-US): Resurgent radiation on the turn; 13/03/2018 – Actinium Announces FDA Clearance of IND for Phase 1 Trial of Actimab-A With CLAG-M for Patients With Relapsed or Refractory AML; 11/04/2018 – Actinium Pharmaceuticals to Showcase Capabilities of its AWE Technology Platform in Developing Biobetters at Upcoming AACR Annual Meeting; 28/03/2018 – Actinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actinium’s AWE Platform Technology

More notable recent Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) news were published by: Prnewswire.com which released: “Actinium Initiates Novel Phase 1/2 Combination Trial of Actimab-A and Venetoclax – PRNewswire” on February 05, 2019, also Prnewswire.com with their article: “Actinium Pharmaceuticals, Inc. to Present at Noble Capital Markets’ 15th Annual Investor Conference – PRNewswire” published on January 25, 2019, Prnewswire.com published: “Actinium Successfully Completes First Module of Collaborative Research Program with Astellas; Second Module Initiated – PRNewswire” on January 17, 2019. More interesting news about Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) were released by: Gurufocus.com and their article: “Actinium Pharmaceuticals Appoints Qing Liang, PhD, DABR as Vice President, Head of Radiation Sciences to Further Innovation for its AWE Technology Platform and Growing Pipeline of Antibody Radiation Conjugate Therapies – GuruFocus.com” published on January 16, 2019 as well as Prnewswire.com‘s news article titled: “Actinium Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference – PRNewswire” with publication date: November 19, 2018.

Investors sentiment increased to 2.11 in Q3 2018. Its up 1.11, from 1 in 2018Q2. It increased, as 7 investors sold Actinium Pharmaceuticals, Inc. shares while 2 reduced holdings. 7 funds opened positions while 12 raised stakes. 8.00 million shares or 19.34% more from 6.70 million shares in 2018Q2 were reported. Baker Ellis Asset Mgmt Lc owns 10,000 shares. Raymond James Fincl Services Inc reported 0% stake. Millennium Mgmt Ltd holds 0% or 16,213 shares. Morgan Stanley holds 17,448 shares or 0% of its portfolio. 1,625 are held by Deutsche Financial Bank Ag. California Public Employees Retirement invested 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Bank & Trust Of Ny Mellon Corp holds 0% of its portfolio in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) for 48,402 shares. Commercial Bank Of America De, North Carolina-based fund reported 960 shares. Hartford Fincl Mgmt Inc stated it has 18,000 shares. Oppenheimer And Inc holds 118,300 shares. 2.58 million were reported by Vanguard Group Inc. Northwestern Mutual Wealth Management holds 0% of its portfolio in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) for 3,232 shares. Northern Tru Corporation holds 0% of its portfolio in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) for 274,065 shares. Pnc Fincl Svcs owns 0% invested in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) for 832,730 shares. Dowling & Yahnke Ltd Liability Com holds 22,870 shares.

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The company has market cap of $60.30 million. The companyÂ’s proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. It currently has negative earnings. The Company’s lead product candidate is Iomab-B that is in Phase III clinical studies in refractory or relapsed acute myeloid leukemia patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant.

Thompson Investment Management Inc increased Mckesson Corp (NYSE:MCK) stake by 4,710 shares to 42,205 valued at $5.60M in 2018Q3. It also upped Celgene Corp Com (NASDAQ:CELG) stake by 11,100 shares and now owns 96,178 shares. Bed Bath & Beyond Inc Com (NASDAQ:BBBY) was raised too.

Among 10 analysts covering Northern Trust (NASDAQ:NTRS), 4 have Buy rating, 1 Sell and 5 Hold. Therefore 40% are positive. Northern Trust had 14 analyst reports since August 16, 2018 according to SRatingsIntel. Morgan Stanley maintained Northern Trust Corporation (NASDAQ:NTRS) rating on Tuesday, January 8. Morgan Stanley has “Underweight” rating and $96 target. The rating was maintained by Raymond James with “Strong Buy” on Thursday, October 18. The firm earned “Neutral” rating on Friday, January 11 by Bank of America. The firm has “Hold” rating given on Thursday, August 16 by Deutsche Bank. Deutsche Bank maintained Northern Trust Corporation (NASDAQ:NTRS) rating on Friday, November 16. Deutsche Bank has “Buy” rating and $107 target. Sandler O’Neill upgraded the shares of NTRS in report on Thursday, October 18 to “Buy” rating. The firm has “Market Perform” rating by Raymond James given on Thursday, January 24. Buckingham Research maintained Northern Trust Corporation (NASDAQ:NTRS) rating on Thursday, October 18. Buckingham Research has “Neutral” rating and $114 target. The stock of Northern Trust Corporation (NASDAQ:NTRS) has “Neutral” rating given on Friday, December 7 by Credit Suisse. Deutsche Bank upgraded it to “Buy” rating and $112 target in Thursday, October 18 report.

More notable recent Northern Trust Corporation (NASDAQ:NTRS) news were published by: Seekingalpha.com which released: “Northern Trust Q4 2018 Earnings Preview – Seeking Alpha” on January 22, 2019, also Seekingalpha.com with their article: “Northern Trust declares $0.60 dividend – Seeking Alpha” published on January 22, 2019, Nasdaq.com published: “Northern Trust (NTRS) Q4 Earnings Top Estimates, Revenues Up – Nasdaq” on January 23, 2019. More interesting news about Northern Trust Corporation (NASDAQ:NTRS) were released by: Nasdaq.com and their article: “Can High Revenues Drive Northern Trust’s (NTRS) Q4 Earnings? – Nasdaq” published on January 21, 2019 as well as Seekingalpha.com‘s news article titled: “Northern Trust Q4 includes $30M tax benefit – Seeking Alpha” with publication date: January 23, 2019.

Investors sentiment increased to 1.27 in Q3 2018. Its up 0.24, from 1.03 in 2018Q2. It improved, as 20 investors sold NTRS shares while 180 reduced holdings. 65 funds opened positions while 188 raised stakes. 171.17 million shares or 0.29% more from 170.67 million shares in 2018Q2 were reported. National Pension has 0.1% invested in Northern Trust Corporation (NASDAQ:NTRS) for 243,077 shares. Srb Corporation invested 0.05% of its portfolio in Northern Trust Corporation (NASDAQ:NTRS). Crawford Counsel accumulated 509,982 shares or 1.59% of the stock. Rafferty Asset Ltd invested in 49,611 shares. Sun Life holds 613 shares. Nomura Asset Management Limited, a Japan-based fund reported 103,884 shares. Credit Suisse Ag reported 334,665 shares. Parallax Volatility Advisers LP has 146 shares. Vigilant Cap Limited Com owns 0% invested in Northern Trust Corporation (NASDAQ:NTRS) for 29 shares. New Mexico Educational Retirement Board holds 0.07% in Northern Trust Corporation (NASDAQ:NTRS) or 18,811 shares. Exane Derivatives reported 1,991 shares. The California-based Aperio Group Incorporated Limited Co has invested 0.07% in Northern Trust Corporation (NASDAQ:NTRS). Sg Americas Securities Limited Com, a New York-based fund reported 9,806 shares. Pinebridge Limited Partnership holds 0.03% or 17,957 shares in its portfolio. Hall Laurie J Trustee has 0.06% invested in Northern Trust Corporation (NASDAQ:NTRS) for 1,030 shares.

Northern Trust Corporation (NASDAQ:NTRS) Institutional Positions Chart



Source link

الوسوم
اظهر المزيد

مقالات ذات صلة

زر الذهاب إلى الأعلى